中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2018, the Group is expected to record consolidated loss for such period.

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on a preliminary assessment by the Company's management on the unaudited consolidated management accounts of the Group and the information currently available to the Group, the board (the "**Board**") of directors (the "**Directors**", each a "**Director**") of the Company wishes to inform the shareholders ("**Shareholders**") and potential investors of the Company that the Group is expected to record a loss for the year end 31 December 2018 as compared to the profit for the corresponding period last year. The Board considers that the aforesaid turning of profit to loss was mainly attributable to (i) the recognition of net loss from the change in fair value of financial liabilities of the convertible preference shares in the Company, and (ii) the recognition of impairment in assets, mainly attributable to the impairment in assets of discontinued operations.

Assessment and valuation shall be made on the change in fair value of financial liabilities of the convertible preference shares in the Company, which shall be subject to the final valuation result made by a professional institution.

The information contained in this announcement is based only on the preliminary assessment by the Board with reference to the information currently available, including the latest unaudited consolidated management accounts of the Group, and is not based on any information or figures which have been audited, confirmed or reviewed by the auditors or the audit committee of the Company. The final results announcement of the Company for the year ended 31 December 2018 is expected to be announced in March 2019.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 30 January 2019

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu, Mr. Wu Weizhong and Mr. Wang Fei; the non-executive Directors are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive Directors are Mr. Patrick Sun, Dr. Hong Yan and Mr. Yu Tze Shan Hailson.